Imugene Limited (ASX:IMU) Reports 57% Complete Response Rate in CAR-T Trial
Clinical Trial Results
Imugene Limited (ASX:IMU) has observed two more Complete Responses in its Phase 1b trial of azer-cel, an allogeneic off-the-shelf CD19 CAR T therapy. This brings the total to four out of seven evaluable patients in Cohort B, achieving a 57% Complete Response rate.
Future Outlook
The trial continues to enroll patients across 13 US sites and five sites in Australia. The longest durability of response is ongoing at 10 months. Additionally, Imugene will present a poster at the 2025 ASTCT Tandem Meetings, showcasing the latest data.
Executive Comments
Dr Paul Woodard, Chief Medical Officer of Imugene, stated, “All four Complete Responses in Cohort B were achieved in patients who had failed at least 4 lines of therapy in this hard-to-treat population, including autologous CAR T therapy. This suggests that azer-cel, in combination with IL-2, may offer a meaningful therapeutic option where other treatments have not succeeded. We are continuing to monitor these patients for persistence of response, with the longest durability ongoing at 10 months. We look forward to providing further updates as data matures.”
Motley Fool contributor Abbie Stokes has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
